We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.91B
1-Year Est. Return 44.39%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+44.39%
3 Year Est. Return
+110.36%
5 Year Est. Return
+52.4%
10 Year Est. Return
+1,142.23%
AUM
$717M
AUM Growth
+$114M
Cap. Flow
-$3.95M
Cap. Flow %
-0.55%
Top 10 Hldgs %
100%
Holding
11
New
4
Increased
2
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AXON
Axon Enterprise
AXON
+$9.39M
2
LCTX icon
Lineage Cell Therapeutics
LCTX
+$6.72M
3
AST
Asterias Biotherapeutics Inc. Series A
AST
+$4.03M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$24.1M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.32%
2 Healthcare 36.42%
3 Miscellaneous 19.81%
4 Industrials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNST icon
1
Monster Beverage
MNST
$87.5B
$304M 42.32%
19,189,632
– –
STAA icon
2
STAAR Surgical
STAA
$1.14B
$168M 23.45%
10,855,179
– –
LCTX icon
3
Lineage Cell Therapeutics
LCTX
$263M
$64.4M 8.98%
34,257,494
+3,077,307
+10% +$6.72M
IWM icon
4
iShares Russell 2000 ETF
IWM
$76.1B
$64M 8.93%
420,000
– –
BA icon
5
PUT
Boeing
BA
$157B
$32.4M 4.52%
+110,000
New +$29.8M
MNST icon
6
PUT
Monster Beverage
MNST
$87.5B
$31.6M 4.41%
+2,000,000
New +$30M
IMDX
7
Insight Molecular Diagnostics
IMDX
$118M
$16.7M 2.33%
179,834
– –
DAL icon
8
PUT
Delta Air Lines
DAL
$50.8B
$14M 1.95%
+250,000
New +$13.1M
AST
9
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$11.9M 1.66%
5,292,156
+1,592,308
+43% +$4.03M
AXON
10
Axon Enterprise
AXON
$38.1B
$10.4M 1.44%
+391,092
New +$9.39M
MNK
11
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-644,822
Closed -$24.1M

Similar funds

EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.91B AUM 19.99% 1-Year Est. Return
RMA
Roffman Miller Associates Philadelphia, Pennsylvania $1.91B AUM 28.29% 1-Year Est. Return
LWMT
Legacy Wealth Management (Tennessee) Memphis, Tennessee $1.91B AUM 17.42% 1-Year Est. Return
FIB
First Interstate Bank Billings, Montana $1.92B AUM 19.65% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $1.92B AUM 6.41% 1-Year Est. Return
HPC
Hill Path Capital New York $1.92B AUM 5.67% 1-Year Est. Return
R
Rebalance Palo Alto, California $1.91B AUM 16.23% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

Broadwood Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Broadwood Capital held 11 positions worth $717M, up 19% from $604M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital's Q4 2017 filing shows 4 new, 2 increased and 1 closed positions. Its largest new stake was Axon Enterprise: 391,092 shares worth $10.4M. The largest sale was MALLINCKRODT PUBLIC LIMITED COMPANY, an estimated $24.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 42% of assets, down from 44% a quarter earlier, followed by Healthcare and Miscellaneous.

  • Broadwood Capital's largest Q4 2017 buy was Axon Enterprise: 391,092 shares worth $10.4M.
  • Broadwood Capital added most to Lineage Cell Therapeutics in Q4 2017, an estimated $6.72M increase.
  • Broadwood Capital fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $24.1M.
  • Broadwood Capital's ten largest holdings make up 100% of its $717M portfolio in Q4 2017.
  • Broadwood Capital opened 4 new positions and closed 1 in Q4 2017.
  • Broadwood Capital's portfolio value rose 19% quarter-over-quarter to $717M.

Based on Broadwood Capital's 13F filing for Q4 2017, filed 14 Feb 2018.